Funding
CHASIT
SECONDARY
The CHASIT study is financially supported by Merck (CrossRef Funder ID: 10.13039/100009945), as part of an alliance between Merck and Pfizer. The funding body has been involved in the study design and selection of primary and secondary outcomes. The funding body has no role in data collection, data analysis nor data interpretation. Merck is the manufacturer of the study drug avelumab. Merck (CrossRef Funder ID: 10.13039/100009945) and Pfizer reviewed this manuscript for medical accuracy only before journal submission. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors.